WO1997040165B1 - Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations - Google Patents
Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisationsInfo
- Publication number
- WO1997040165B1 WO1997040165B1 PCT/US1997/006866 US9706866W WO9740165B1 WO 1997040165 B1 WO1997040165 B1 WO 1997040165B1 US 9706866 W US9706866 W US 9706866W WO 9740165 B1 WO9740165 B1 WO 9740165B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immunogenic composition
- pδrc
- group
- hcmv
- human cytomegalovirus
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title claims abstract 15
- 238000000034 method Methods 0.000 claims abstract 12
- 239000013612 plasmid Substances 0.000 claims abstract 7
- 230000028993 immune response Effects 0.000 claims abstract 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract 3
- 102000004169 proteins and genes Human genes 0.000 claims abstract 3
- 230000002163 immunogen Effects 0.000 claims 20
- 108020004414 DNA Proteins 0.000 claims 9
- 102000053602 DNA Human genes 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 101150029683 gB gene Proteins 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000037452 priming Effects 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 210000002845 virion Anatomy 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Abstract
L'invention concerne des molécules d'ADN nouvelles servant à exprimer in vitro et in vivo le complexe gB du cytomégalovirus humain et des dérivés du complexe gB dont la transmembrane a été supprimée, tels que les protéines pp65, pp150 et IE-exon-4. Ces molécules sont de préférence des plasmides. L'invention concerne également des procédés d'utilisation de ces molécules d'ADN de façon à induire des réponses immunitaires en réaction au cytomégalovirus humain, et l'utilisation d'un plasmide de la présente invention, qui sert à amorcer des réponses immunitaires lors de l'administration de vaccins contre le cytomégalovirus humain.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/171,699 US6448389B1 (en) | 1996-04-23 | 1997-04-22 | Human cytomegalovirus DNA constructs and uses therefor |
| AU28098/97A AU2809897A (en) | 1996-04-23 | 1997-04-22 | Novel human cytomegalovirus dna constructs and uses therefor |
| EP97922429A EP0914441A2 (fr) | 1996-04-23 | 1997-04-22 | Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1571796P | 1996-04-23 | 1996-04-23 | |
| US60/015,717 | 1996-04-23 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/171,699 A-371-Of-International US6448389B1 (en) | 1996-04-23 | 1997-04-22 | Human cytomegalovirus DNA constructs and uses therefor |
| US10/223,538 Division US20030120060A1 (en) | 1996-04-23 | 2002-08-19 | Human cytomegalovirus DNA constructs and uses therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1997040165A1 WO1997040165A1 (fr) | 1997-10-30 |
| WO1997040165B1 true WO1997040165B1 (fr) | 1998-01-08 |
| WO1997040165A9 WO1997040165A9 (fr) | 1998-02-12 |
Family
ID=21773167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/006866 WO1997040165A1 (fr) | 1996-04-23 | 1997-04-22 | Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US6448389B1 (fr) |
| EP (1) | EP0914441A2 (fr) |
| AU (1) | AU2809897A (fr) |
| WO (1) | WO1997040165A1 (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2809897A (en) | 1996-04-23 | 1997-11-12 | Wistar Institute Of Anatomy And Biology, The | Novel human cytomegalovirus dna constructs and uses therefor |
| WO1998006408A1 (fr) | 1996-08-14 | 1998-02-19 | The Wistar Institute Of Anatomy And Biology | Procedes et compositions pour empecher ou pour retarder le developpement de lesions atherosclereuses |
| US6562345B1 (en) | 1996-11-12 | 2003-05-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| AU4351900A (en) * | 1999-04-15 | 2000-11-02 | Board Of Regents, The University Of Texas System | Inducible vaccines |
| EP1612217A3 (fr) * | 2000-03-27 | 2006-01-18 | City of Hope | Epitopes ctl peptidiques immunoréactifs du cytomégalovirus |
| US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
| JP2004504038A (ja) | 2000-07-13 | 2004-02-12 | ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン | 多発性嚢胞腎疾患の検出と治療 |
| AU2001293798B2 (en) * | 2000-09-09 | 2006-12-21 | Basf Plant Science Gmbh | Modified tet-inducible system for regulation of gene expression in plants |
| JP4099058B2 (ja) | 2000-10-20 | 2008-06-11 | シティ・オブ・ホープ | ヒトサイトメガロウィルスｐｐ１５０の免疫反応性ペプチドｃｔｌエピトープ |
| DE60233061D1 (de) * | 2001-09-06 | 2009-09-03 | Alphavax Inc | Alphavirus replikon-vektorsysteme |
| AU2003301148A1 (en) | 2002-12-23 | 2004-07-22 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
| WO2004074439A2 (fr) * | 2003-02-14 | 2004-09-02 | Biogen Idec Ma Inc. | Cassette et vecteur d'expression pour l'expression transitoire ou stable de molecule exogenes |
| WO2004076645A2 (fr) * | 2003-02-27 | 2004-09-10 | University Of Massachusetts | Compositions et methodes de traitement du cytomegalovirus |
| KR101518309B1 (ko) * | 2003-03-20 | 2015-05-08 | 알파벡스, 인크. | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 |
| DK1651666T3 (da) * | 2003-07-11 | 2009-08-31 | Alphavax Inc | Alfavirus-baserede cytomegalovirusvacciner |
| WO2006004661A1 (fr) * | 2004-06-25 | 2006-01-12 | Medimmune Vaccines, Inc. | Cytomegalovirus humain de recombinaison et vaccins contenant des antigenes heterologues |
| ES2670813T3 (es) * | 2007-06-21 | 2018-06-01 | Alphavax, Inc. | Partículas de replicón de alfavirus para uso en vacunación |
| WO2009155535A2 (fr) * | 2008-06-20 | 2009-12-23 | Duke University | Compositions, procédés et kits permettant d’obtenir une réponse immunitaire |
| US8812387B1 (en) | 2013-03-14 | 2014-08-19 | Csidentity Corporation | System and method for identifying related credit inquiries |
| EP3052106A4 (fr) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucléotides codant des polypeptides de modulation immunitaire |
| CN106102769A (zh) * | 2013-12-11 | 2016-11-09 | 促进军事医学的亨利·M·杰克逊基金会公司 | 人疱疹病毒三聚糖蛋白B、包含三聚gB的蛋白复合体及其作为疫苗的用途 |
| WO2017070613A1 (fr) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Vaccin contre le cytomégalovirus humain |
| RU2616245C2 (ru) * | 2015-12-29 | 2017-04-13 | Сейфаддин Гашим Оглы Марданлы | Композиция для профилактики заболеваний, вызываемых цитомегаловирусной инфекцией |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| TWI871709B (zh) | 2020-06-21 | 2025-02-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3959466A (en) | 1974-04-15 | 1976-05-25 | The Wistar Institute | Highly attenuated cytomegalovirus vaccine and production thereof |
| ZA858044B (en) | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
| US4689225A (en) | 1984-11-02 | 1987-08-25 | Institut Merieux | Vaccine for cytomegalovirus |
| CA1335429C (fr) | 1986-03-07 | 1995-05-02 | Geoffrey L. Smith | Procedes de fabrication de glycoproteines hcmv, les anticorps et les vaccins diriges contre ces glycoproteines hcmv, et leurs vecteurs recombinants |
| DE3619720A1 (de) | 1986-06-12 | 1987-12-17 | Behringwerke Ag | Hauptglykoprotein des menschlichen cytomegalovirus, seine herstellung und verwendung |
| EP0252531B1 (fr) | 1986-06-12 | 1992-12-02 | BEHRINGWERKE Aktiengesellschaft | Phosphoprotéine structurale (pp 150) de cytomégalovirus humain, sa préparation et son utilisation |
| DE3619902A1 (de) | 1986-06-13 | 1988-03-03 | Biotechnolog Forschung Gmbh | Cmv-dna-strukturen, expressionsvektor dafuer, cmv-proteinstrukturen und deren verwendung |
| ZA878031B (en) | 1986-11-04 | 1988-04-28 | Scripps Clinic And Research Foundation | Nucleic acid probes for the detection of latent human cytomegalovirus in blood products |
| US5124440A (en) | 1986-11-24 | 1992-06-23 | The Childrens Hospital, Inc. | Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus |
| US5153311A (en) | 1986-11-24 | 1992-10-06 | The Children's Hospital, Incorporated | Immunogenic glycoproteins of human cytomegalovirus gCII |
| EP0277773A1 (fr) | 1987-01-30 | 1988-08-10 | The Board Of Trustees Of The Leland Stanford Junior University | Cytomégalovirus hybride et vaccin |
| ATE246244T1 (de) | 1988-01-29 | 2003-08-15 | Aventis Pasteur | Rekombinante cmv-neutralisierungsproteine |
| JPH03505457A (ja) | 1988-07-01 | 1991-11-28 | ザ・チルドレンズ・ホスピタル，インコーポレイテッド | サイトメガロウイルス由来のフラグメントの抗体認識 |
| WO1990006771A1 (fr) | 1988-12-12 | 1990-06-28 | The Children's Hospital, Incorporated | Fragments proteolytiques obtenus a partir du complexe i de glycoproteines de cytomegalovirus humain |
| US5552143A (en) | 1989-03-24 | 1996-09-03 | The Wistar Institute Of Anatomy & Biology | Recombinant cytomegalovirus vaccine |
| ES2091221T3 (es) | 1989-03-24 | 1996-11-01 | Wistar Inst | Vacuna de citomegalovirus recombinante. |
| US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
| WO1991002004A1 (fr) | 1989-08-07 | 1991-02-21 | Children's Biomedical Research Center | GLYCOPROTEINES IMMUNOGENIQUES DU CYTOMEGALOVIRUS HUMAIN gCII |
| AU7906691A (en) | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
| GB9014652D0 (en) | 1990-07-02 | 1990-08-22 | Wellcome Found | Antigen |
| EP0541721A4 (en) | 1990-08-02 | 1993-12-29 | Chiron Corporation | Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| WO1994017810A1 (fr) | 1993-02-12 | 1994-08-18 | The Wistar Institute Of Anatomy And Biology | Vaccin recombine contre le cytomegalovirus |
| EP0708658A4 (fr) | 1993-04-16 | 1997-05-21 | Wistar Inst | Vaccin contenant un cytomegalovirus de recombinaison |
| IT1266740B1 (it) | 1994-07-01 | 1997-01-14 | Maria Paola Landini | Materiale proteico ricombinante legante anticorpi contro il citomegalovirus umano, reagenti diagnostici derivati da tale |
| AU2809897A (en) | 1996-04-23 | 1997-11-12 | Wistar Institute Of Anatomy And Biology, The | Novel human cytomegalovirus dna constructs and uses therefor |
-
1997
- 1997-04-22 AU AU28098/97A patent/AU2809897A/en not_active Abandoned
- 1997-04-22 US US09/171,699 patent/US6448389B1/en not_active Expired - Lifetime
- 1997-04-22 EP EP97922429A patent/EP0914441A2/fr not_active Withdrawn
- 1997-04-22 WO PCT/US1997/006866 patent/WO1997040165A1/fr not_active Application Discontinuation
-
2002
- 2002-08-19 US US10/223,538 patent/US20030120060A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1997040165B1 (fr) | Nouveaux produits de construction d'adn de cytomegalovirus humain, et leurs utilisations | |
| Prehaud et al. | Immunogenic and protective properties of rabies virus glycoprotein expressed by baculovirus vectors | |
| Osterrieder et al. | Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB) | |
| EP0139417B1 (fr) | Vaccins à base de protéines liées à des membranes et procédé pour leur préparation | |
| Yoo et al. | The S2 subunit of the spike glycoprotein of bovine coronavirus mediates membrane fusion in insect cells | |
| CA2228221A1 (fr) | Produits de recombinaison de polyproteine de papillomavirus | |
| EP0486170B1 (fr) | Système d'expression baculoviral comportant une séquence leader procaryote | |
| Konishi et al. | A vipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens | |
| CA2275340A1 (fr) | Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin | |
| EP0538341B1 (fr) | Vaccin a base de glycoproteine de vhe-4 (virus d'herpes equin-4) | |
| Sarkar et al. | Polypeptides of the mouse mammary tumor virus: II. Identification of two major glycoproteins with the viral structure | |
| ALLEN et al. | Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity | |
| EP0117657A1 (fr) | Polypeptides immunogènes contre la rage et vaccin utilisant ces peptides, séquences d'ADN, vecteurs d'expression, cellules recombinantes, cultures et procédés pour leur production | |
| Meindl et al. | The equine herpesvirus 1 Us2 homolog encodes a nonessential membrane-associated virion component | |
| DE69534162T2 (de) | Fusion-glykoprotein von hcmv und hsv | |
| WO1998012333A1 (fr) | Peptides immunogenes des virus de la fievre aphteuse | |
| JP2003230396A (ja) | ｇｐ３５０／２２０非スプライシング変異体 | |
| EP0913157B1 (fr) | Vaccin composite contenant un antigene, un anticorps et un adn recombinant et son procede de preparation | |
| JP2852395B2 (ja) | ネコ白血病ウイルスワクチン | |
| Frenchick et al. | Biochemical and immunological characterization of a novel peptide carrier system using rotavirus VP6 particles | |
| WO1997003187A3 (fr) | Genes du virus de la maladie de marek et leur utilisation dans des vaccins qui protegent contre la maladie de marek | |
| EP0471457A2 (fr) | Vecteur herpesviral exprimant un épitope du virus de la fièvre aphteuse | |
| KR100768051B1 (ko) | 간염 바이러스 ｏｒｆ2의 ｎ-말단 영역으로부터 유래한프로세싱 성분 및 항원성 폴리펩티드를 암호화하는 핵산구성물 | |
| Osterrieder et al. | Deletion of gene 52 encoding glycoprotein M of equine herpesvirus type 1 strain RacH results in increased immunogenicity | |
| Chikateru et al. | Expression of herpes simplex virus glycoprotein B gene in yeast |